Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NePHera: Trastuzumab and Pertuzumab Biosimilars in Rectal Cancer
NCT07108127Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab, pertuzumab in rectal cancer, sponsored by Peking Union Medical College Hospital. Started Jun 2025; status: recruiting.
02
Drugs
trastuzumabpertuzumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07108127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07108127.